Search the Newsreel

Xeris (XERS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Senior Vice President of Investor Relations - Allison Wey Chairman and Chief Executive Officer - John Shannon Chief Financial Officer - Steven Pieper Full Conference Call Transcript Operator: …

Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares

Xeris Biopharma insider Steven Pieper has filed to sell 20,000 common shares under Rule 144, with an aggregate market value of $167,800.00, to be handled by Morgan Stanley Smith Barney LLC. These shares originated from Restricted Stock Units granted in January 2025. This planned …

Xeris Biopharma’s Rising Revenue And Wider Losses Could Be A Game Changer For XERS

Xeris Biopharma Holdings Inc (XERS) Stock News Today

This article provides current stock information for Xeris Biopharma Holdings Inc (XERS) including its recent closing price, market capitalization, and P/E ratio. It highlights that the company's stock experienced a gain of 7.74% and indicates that more news and earnings updates are expected soon …

Should Xeris Biopharma Holdings (XERS) Be Revalued After Strong Q2 Revenue And Fresh Guidance?

Xeris Biopharma Holdings (XERS) is attracting investor attention following its Q2 earnings report, which included strong performance and a refined full-year 2026 revenue outlook. The stock is currently trading at $7.93, with a recent 7.74% one-day return, and analysts consider it undervalued with a …

Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses

Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary

Xeris Biopharma Holdings, Inc. reported its 2026 quarterly results with revenue reaching $92.1 million, an increase of 28.7% year-over-year. Despite the revenue growth, the company recorded a net loss of ($31.1M) and a diluted EPS of ($0.18), driven by higher product sales and increased …

Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings Summary

Xeris Biopharma Holdings, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is provided by Refinitiv and is available to TradingView users with unlimited access to news articles.

Xeris Pharmaceuticals’ Earnings Call Highlights Growth Momentum

Key Points Interested in Xeris Biopharma Holdings, Inc.? Here are five stocks we like better. Xeris Biopharma's second-quarter revenue rose 29% year over year to $92.1 million, driven by a 34% increase in net product revenue. Adjusted EBITDA grew more than 50% to $19.3 …

Xeris Pharmaceuticals earnings missed by $0.19, revenue topped estimates

Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss

Xeris Biopharma reported a Q2 2026 revenue beat of $92.1 million, surpassing Wall Street estimates, but missed EPS expectations with a loss of $0.18 per share. The company attributed the EPS miss primarily to a one-time non-cash GAAP charge related to convertible note remeasurement. …

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

Xeris Biopharma (XERS) reported Q2 2026 revenue of $92.1 million, a 28.7% year-over-year increase, surpassing the Zacks Consensus Estimate. However, the EPS of $0 missed the consensus estimate of $0.02. Key product revenues varied, with Recorlev showing significant growth while Gvoke and Keveyis experienced …

(XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M - $390M, vs. FactSet Est of $385.9M

Xeris Biopharma Holdings, Inc. announced its full-year 2026 revenue guidance, projecting a range of $385 million to $390 million. This forecast is in line with FactSet's estimated revenue of $385.9 million. The company also provided an update on its second-quarter earnings for 2026.

Xeris Biopharma (NASDAQ:XERS) Shares Gap Down Following Weak Earnings

Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock

Kevin Mcculloch, an insider at Xeris Biopharma (NASDAQ:XERS), sold 15,000 shares of the company's stock for $120,300 on August 3rd, reducing his total holdings by 0.89%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. The company's stock has shown positive performance, …

Xeris Biopharma (XERS) Insider Beth Hecht Sells 16,666 Shares

Xeris Biopharma insider Beth Hecht sold 16,666 shares of XERS for $8.01 per share on August 3, 2026, totaling approximately $133,495. This

Xeris Biopharma President, COO Kevin McCulloch sells 15,000 shares for $120,240

Xeris Biopharma President and COO Kevin McCulloch sold 15,000 common shares for $120,240 on August 3, 2026, at a price of $8.02 per share. Following this transaction, his direct stake increased to 1,676,126 shares. The report also noted his spouse indirectly holds 25,000 shares.

Vanguard Capital Management (XERS) discloses 8.64M-share, 5% holding in Xeris

Vanguard Capital Management LLC and its affiliates have reported a 5% beneficial ownership stake in Xeris Biopharma Holdings Inc, amounting to 8,637,640 common shares. This disclosure, made via a Schedule 13G filing, indicates that Vanguard holds sole voting power over 1,297,411 shares and sole …

XERS|Xeris Biopharma Holdings Inc|Price:8.415|Chg%:+0.035

This article provides a detailed financial overview of Xeris Biopharma Holdings Inc (XERS), including its stock price, market cap, P/E ratio, and upcoming earnings date. It presents comprehensive financial statements like the income statement, balance sheet, and cash flow statement, broken down quarterly and …

Xeris Biopharma (XERS) Expected to Release Quarterly Earnings on Thursday

Xeris Biopharma (XERS) is scheduled to release its Q2 2026 earnings before market open on Thursday, August 6th. Analysts project earnings of $0.02 per share and approximately $90.1 million in revenue. The company currently holds a "Moderate Buy" consensus rating with an average price …

Xeris Biopharma Holdings Inc (XERS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Xeris Biopharma Holdings Inc (XERS), noting its current valuation score of 8.01 within the Pharmaceuticals industry. It highlights the company's P/E ratio of 104.89, which is significantly below its recent high but above its recent low. Key …

Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Xeris Biopharma Holdings Inc (XERS), detailing its current price momentum, support and resistance levels, and various technical indicators. The stock's price momentum score is 3.43, and it is trading between a resistance level of $8.98 and a …

Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Xeris Biopharma Holdings Inc (XERS) has an earnings forecast score of 8.57, ranking 26th in the Pharmaceuticals industry. Analysts have an average price target of $10.00 for XERS, with a consensus "Buy" rating based on 7 analysts. The expected revenue for the next quarter …

Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS

Rice Hall James & Associates LLC recently acquired 251,066 shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) worth approximately $1.46 million, contributing to institutional and hedge fund ownership of 42.75% of the company. Analysts maintain a "Moderate Buy" rating with a consensus target price of …

Xeris Biopharma Holdings Inc (XERS) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Xeris Biopharma Holdings Inc (XERS), covering operating, investing, and financing activities. It presents financial data from FY2017Q1 through FY2026Q1, allowing users to evaluate the company's financial soundness. The report also includes FAQs …

Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides an overview of Xeris Biopharma Holdings Inc (XERS) focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock price information, …

Xeris Biopharma Holdings, Inc. Revenue Breakdown – NASDAQ:XERS

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) generated a total revenue of $291.85 million USD last year. The primary segment contributing to this revenue was "Gvoke, Keveyis and Recorlev," which brought in $283.00 million USD. The vast majority of the company's revenue, $291.85 million USD, was …

Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Granahan Investment Management LLC

Granahan Investment Management LLC reduced its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 24.6% in the first quarter, selling 301,550 shares and retaining 921,854 shares valued at approximately $5.35 million. This divestment comes amidst mixed signals, with Weiss Ratings upgrading Xeris from "sell" …

XERS|Xeris Biopharma Holdings Inc|Price:8.320|Chg%:-0.090

Xeris Biopharma Holdings Inc (XERS) is currently trading at $8.32, down 1.07%. The company has healthy fundamentals, high growth potential, and is considered fairly valued within the Pharmaceuticals industry. Analysts have a "Buy" rating for XERS, with a target price of $11.29, suggesting a …

Xeris Biopharma to report Q2 results, host conference call

Xeris Biopharma Holdings Inc. will release its second-quarter 2026 financial results before the U.S. market opens on August 6, 2026. The company will also host a conference call and webcast on the same day at 8:30 a.m. ET to discuss the results. This news …

Xeris Biopharma Holdings Inc (XERS) Fundamental & Financial Data

This article provides fundamental and financial data for Xeris Biopharma Holdings Inc (XERS). It lists key financial metrics such as market capitalization, current price, dividend yield, PE ratio, and 52-week high/low. The article also includes recent news and earnings information for XERS.

Xeris Biopharma to report Q2 2026 results on Aug 6

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) will announce its second-quarter 2026 financial results on August 6, 2026, before market open. A conference call and webcast will follow at 8:30 a.m. ET to discuss the performance of its commercial products Recorlev, Gvoke, and Keveyis, and …

XERS5927663 Bond Coupon Profile — Rate & Payments

This article provides a coupon profile for the Xeris Biopharma Holdings, Inc. bond, XERS5927663. It details that the bond has a current coupon rate of 8.00% and its next interest payment is scheduled for January 15, 2027. The article offers an overview of the …